A preclinical model of peripheral T-cell lymphoma GATA3 reveals DNA damage response pathway vulnerability

Area of Science:

• Oncology
• Immunology
• Genetics

Background:

• Peripheral T-cell lymphoma (PTCL) is a rare, aggressive cancer lacking effective treatments.
• Preclinical models are crucial for understanding PTCL but are currently scarce.
• Existing models do not fully recapitulate the complexity of human PTCL.

Purpose of the Study:

• To develop a novel, immunocompetent mouse model for PTCL.
• To investigate the molecular and immunological drivers of T-cell lymphomagenesis.
• To identify potential therapeutic targets for PTCL.

Main Methods:

• Serial transplantation of lymphoma in immunocompetent mice to establish a novel mouse PTCL (mPTCL) model.
• Flow cytometry and molecular profiling (gene expression, exome sequencing) to characterize lymphoma cells and pathways.
• In vivo and in vitro efficacy studies of ATR inhibition targeting the DNA damage response (DDR).

Main Results:

• Established a novel mPTCL model with clonal T-helper cells expressing T-follicular helper markers.
• Observed coincident B-cell activation and lymphomagenesis, mirroring human PTCL.
• Molecular profiling revealed the mPTCL aligns with the high-risk GATA3 subtype, featuring GATA3/Th2 expression, PI3K/mTOR enrichment, MYC hyperactivation, and genome instability.
• Identified a human-relevant oncogenic β-catenin mutation.
• ATR inhibition targeting DDR demonstrated prolonged therapeutic responses in vivo and in vitro.

Conclusions:

• The novel mPTCL model provides valuable insights into T-cell lymphomagenesis and associated B-cell abnormalities.
• The study implicates GATA3, Th2 pathways, PI3K/mTOR, MYC, and β-catenin in PTCL development.
• DNA damage response (DDR) inhibition represents a promising and translatable therapeutic strategy for PTCL.